NCT00962767 2009-08-20
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Completed